Navigation Links
Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
Date:10/22/2013

airs/biosimilars_policy_positions/index">policy paper on biosimilars naming, in which he draws on his own experience as a physician prescribing medications.

Biosimilars are biologic medicines proven to have similar clinical effects as biologics, but at a more affordable cost to both the healthcare system and patients. In Europe, biosimilars have helped lower costs by 20 percent to 30 percent[i]. It's estimated that biosimilars could save the U.S. healthcare system $20 billion annually[ii]. The U.S. biosimilars market is expected to develop around mid-decade[i].

Learn more about how biosimilars will impact healthcare at www.hospira.com/biologics

Hospira is the first U.S. company to sell biosimilars in Europe, launching its erythropoietin product, Retacrit™ in early 2008. It also sells Nivestim™, a filgrastim biosimilar, in Europe and Australia, and in 2013 received European approval for Inflectra™, its biosimilar version of infliximab. Hospira is currently conducting a Phase III U.S. clinical trial program for its U.S. epoetin product, which is being developed as a biosimilar to erythropoietin alfa.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 16,000 employees. Learn more at www.hospira.com.

[i] IMS Intelligence Incorporated. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. 2011 December. Section 1, Page 2.

[ii] "New Grant T
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
2. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
3. Biosimilars: Global Markets
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
6. Biosimilars Market Expected to Soar
7. Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
8. XBiotech Expands Portfolio to Include Biosimilars
9. Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars
10. Seminar Spotlights Key Trends in Biologics and Biosimilars
11. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to announce ... Charlottetown , PEI.  Bioenterprise has established ... ADAPT Council for the commercialization of agricultural technologies and ... with PEI ADAPT.  They have been at the heart ... decade," explains Dave Smardon , President & CEO ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... N.J., Jan. 21 Wedgewood Pharmacy has,announced ... (Bevacizumab) to,retinal specialists and ophthalmologists who request ... Avastin,s manufacturer, Genentech,s, decision,( http://www.lucentis.com/lucentis/pdf/announcement.pdf ) to ... of January 1., Avastin is commonly ...
... 21 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... of portions of the recently completed and ... planning for 2008,and employee recognition ceremonies., ... Mr. Zhang, Director and General Manager of ...
... chocolate present risk, OAKLAND, Calif., Jan. 21 ... whether from coffee, tea, caffeinated soda or hot,chocolate ... a new study,by the Kaiser Permanente Division of ... symptoms of nausea, vomiting and caffeine,aversion that tended ...
Cached Biology Technology:Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3Kiwa Posts Video of 2007 Annual Management Meetings 2Kiwa Posts Video of 2007 Annual Management Meetings 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... get a jump on the latest news in science and ... Research Day set for Nov. 9, 2011. The event, ... for the best and brightest graduate students to display their ... Students from Stevens Institute of Technology, Rutgers University -- Newark ...
... first DNA barcoding survey of crustaceans living on samples of ... The results suggest that the diversity of organisms living on ... "The Diversity of Coral Reefs: What Are We Missing?" was ... At depths of 26 to 39 feet, the ...
... Nov. 2In the emerging field of tissue engineering, scientists ... The ultimate goal is to create living structures that ... damaged tissue, but the manufacture of appropriately detailed scaffolds ... engineering applications confined to the research lab. Now a ...
Cached Biology News:NJIT grad students display work at 7th annual Research Day on Nov. 9 2New study reveals coral reefs may support much more biodiversity than previously thought 2Manufacturing microscale medical devices for faster tissue engineering 2Manufacturing microscale medical devices for faster tissue engineering 3
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: